Greater than 25% of all
cancers have oncogene amplifications
More than 5 million newly diagnosed cancers each year around the world harbor oncogene amplifications. Unfortunately, there are no effective treatment options for the vast majority of these patients, resulting in poor prognosis and survival.
Despite substantial advances in the development of therapies for patients with cancers driven by oncogene mutations or fusions, the current generation of targeted therapies and immunotherapies has proven largely ineffective in patients with cancers driven by oncogene amplification.
ecDNA drive
oncogene amplifications
Extrachromosomal DNA (ecDNA) are large circular units of nuclear DNA, physically distinct from chromosomes, that are a primary mechanism of gene amplification and, like oncogene amplifications, are detected only in cancer cells, not in healthy cells.
Through the work of our experienced team, supported by our field-leading scientific founders, we are elucidating how these circular DNA structures play an aggressive and central role in tumor growth and evolution. Frequently encoding oncogenes or other cell survival factors, ecDNA enable cancer to rapidly grow, evolve, and evade therapeutic intervention.
Boundless Bio’s differentiated therapeutic approach is to leverage our proprietary Spyglass platform (see What We Do) to identify cancer-specific liabilities that accompany cancer cells’ reliance on ecDNA.
ecDNA are a
therapeutically actionable, unique vulnerability of cancer cells
ecDNA are rarely seen in healthy cells but are found in the cancer cells of over 17% of patients with solid tumor. Boundless Bio’s comprehensive approach to understanding the utilization of ecDNA by cancer allows us to identify and therapeutically exploit unique vulnerabilities of ecDNA in cancer cells.
Why Boundless Bio?
Boundless Bio is the first company dedicated to treating oncogene amplified cancers and is the leader in the field of ecDNA, driving the discovery and development of a novel therapeutic approach to targeting oncogene amplified cancers.
With boundless innovation and boundless energy, our team of professional drug hunters is committed to developing powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.